Ambicion

AMBICION Co., Ltd.

MENU

News

AMBICION has completed raising funds from Regional Health Care Industry Support Fund and TOHO HOLDINGS

April 18, 2018

AMBICION Co., Ltd. announced that it has completed raising funds from Regional Health Care Industry Support Fund and TOHO HOLDINGS CO., LTD. through third-party allocation of new shares.
With this capital increase, AMBICION accelerates its development programs of Natural Killer T (NKT) cell-t...

AMBICION and RIKEN Enter into the Global Exclusive Licensing Agreements for Natural Killer T (NKT) Cell-Targeted Anti-Cancer Therapy

March 30, 2018

AMBICION (CEO: Yoshiyuki Saito) announced that RIKEN (President: Hiroshi Matsumoto) and AMBICION entered into the global exclusive licensing agreements on RIKEN patent regarding Natural Killer T (NKT) cell-targeted anti-cancer therapy. Under the terms of the licensing agreement, AMBICION has been ...

AMBICION collaborates with Keio University Hospital and RIKEN on the clinical trial of the newly developed Natural Killer T (NKT) cell targeted anti-cancer therapy

March 12, 2018

AMBICION starts to supply the investigational product to a phase I study of the newly developed Natural Killer T (NKT) cell-targeted anti-cancer therapy conducted by Keio University Hospital. This clinical trial evaluates the safety and efficacy of an investigational product that activates patient i...